Health / Medical Topics

    hTERT/Survivin/Melanoma Tumor Cell-Derived mRNA-Transfected Dendritic Cell Vaccine

    A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival. (NCI Thesaurus)




    YOU MAY ALSO LIKE

    A vaccine containing multiple peptides derived from the human telomerase reverse transcriptase (hTERT), survivin and cytomegalovirus (CMV), with potential immunostimulating and antineoplastic…
    A cancer vaccine directed against human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with potential immunostimulating and antineoplastic…
    A cancer vaccine containing autologous dendritic cells (DCs) that are pulsed with mRNA encoding human telomerase reverse transcriptase (hTERT) and survivin peptide,…
    A peptide vaccine consisting of multiple epitopes derived from the human telomerase reverse transcriptase (hTERT), the catalytic subunit of human telomerase, with…
    Human HTC2 gene is located within Xq24-q27.1 and the size of this phenotypic locus is not reported. This gene region has no…
    Human HTATIP2 wild-type allele is located in the 11p15.1 and is approximately 20 kb in length. This allele, which encodes oxidoreductase HTATIP2…

    © 1991-2023 The Titi Tudorancea Bulletin | Titi Tudorancea® is a Registered Trademark | Terms of use and privacy policy
    Contact